Luye Pharma Converts $25 Million of Tranche A Bonds
I'm PortAI, I can summarize articles.
Luye Pharma Group Ltd. has converted US$25 million of its Tranche A Bonds at a conversion price of HK$3.672 per share. This is part of a broader financial strategy involving US$100 million in convertible bonds due in 2025, potentially affecting its financial structure and investor relations. The latest analyst rating for Luye Pharma (HK:2186) is a Buy, with a price target of HK$5.00. Luye Pharma focuses on innovative pharmaceutical products, primarily in the Chinese market, and has a current market cap of HK$14.49 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments